| |
ESMI (Spain)
|
SFH (USA)
|
ECLIPSE
|
|---|
|
Hospitalized
|
Hospitalized
|
Out-Patients
|
|---|
|
On O2 rx (%)
|
39
|
53
|
-
|
|
FEV1 % predicted
|
43
|
47
|
48
|
|
G2; G3; G4 (%)
|
45; 44; 11
|
-
|
44; 42; 14
|
|
FEV1/FVC ≥ 0.70 (% of sample)
|
-
|
21
| |
|
Could not/would not do 6 MWT (%)
|
-
|
20
|
-
|
|
6MWT distance (meters)
|
-
|
157
|
All: 370
|
|
G2: 406
|
|
G3: 357
|
|
G4: 290
|
- O2, Oxygen; FEV1, Forced expiratory volume in one second; FVC, Forced vital capacity
- G2, Global Initiative for Obstructive Lung Disease (GOLD) spirometric stage 2 (FEV1 ≥ 50 % and < 80 %); G3, GOLD spirometric stage 3 (FEV1 ≥ 30 % and < 50 %); G4, GOLD spirometric stage 4 (FEV1 < 30 %). 6MWT, six minute walk test
